Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab

  • Technology appraisal guidance
  • TA612
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence